Intelligent Bio Solutions (INBS) is providing an update on the timeline for anticipated FDA 510(k) clearance for the use of its Intelligent Fingerprinting Drug Screening System, IFDSS, for the opiate codeine. nFollowing recent feedback from the U.S. Food and Drug Administration, INBS has established a pathway to gather additional supporting data to strengthen its new 510(k) submission to the FDA. The Company plans to commence clinical studies to further validate its Intelligent Fingerprinting Drug Screening System before calendar year-end. These studies are scheduled to conclude in the first half of the 2026 calendar year. INBS anticipates FDA 510(k) clearance in the second half of the 2026 calendar year.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INBS:
- Intelligent Bio Solutions Extends Warrant Termination Date
- FDA Requests More Info from Intelligent Bio Solutions
- Intelligent Bio Solutions provides update on FDA 510k clearance process
- Intelligent Bio Solutions files to sell 4.15M shares of common stock for holders
- Intelligent Bio achieves monthly sales of 12,500+ units of cartridges in July